Introduction by the column editor: Interactions between the pharmaceutical industry and clinicians have important consequences for patient care. So a "best practices" look at this topic is welcomed. The authors of this month's column have initiated a quality-assurance process in their organization by developing ethical guidelines for such interactions. Guidelines are an early step toward the ultimate achievement of best practices. Over time, with monitoring of the impact of their guidelines on their institution, these authors will understand more about this vital theme. Attempts by other clinical organizations to develop guidelines will be needed to add to a generalized strategy for interactions between the pharmaceutical industry and the clinician.